Nasdaq:SABS
SAB Biotherapeutics, Inc.
A Nasdaq-listed biotech firm advancing cell therapy solutions for cancer patients while managing significant cash burn and limited current revenue.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe in the transformative potential of its cell therapy platform for oncology markets. The company holds sufficient cash equivalents and marketable securities to continue operations without immediate dilution risks. Strategic partnerships could unlock future revenue streams once clinical trials progress toward commercial milestones.
Bear Case
The severe decline in revenue over five years and persistent negative net income suggest fundamental business model challenges or failed product transitions. Negative operating cash flow of $34.3M indicates an inability to generate self-sustaining earnings without continuous capital raises. High fixed costs including general and administrative expenses of $14.0M create pressure on thin gross profits of only $1.3M.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics Inc. is a biopharmaceutical company focused on developing advanced cell therapies for cancer treatment, serving markets in oncology and immunotherapy. The company leverages its proprietary technology platforms to create personalized cellular medicines for various solid tumor types. Key products are in clinical development stages with revenue primarily derived from grants, collaborations, or early-stage commercial activities.
Analysis
Management Discussion
The company reported a net loss of $34.1M in the latest period with operating expenses reaching $44.2M, driven largely by R&D investments of $30.3M. Despite cash flow from financing inflows partially offsetting operational outflows, the net change in cash turned negative at -$47.7M due to substantial investing outflows. Revenue declined sharply over the past three years as the company prioritizes pipeline development over commercialization.
Industry Overview
The biotechnology sector is characterized by high R&D expenditures, long development cycles, and significant regulatory hurdles before product approval. Companies in cell therapy face intense competition from established pharmaceutical giants and emerging biotech firms targeting similar indications. Success depends heavily on clinical trial outcomes and the ability to secure funding during pre-revenue stages.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $23.9M | $2.2M | $1.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $23.9M | $2.2M | $1.3M |
| Operating Expenses | $52.8M | $40.3M | $44.2M |
| Operating Income | $-28.9M | $-38.1M | $-42.9M |
| R&D | $36.4M | $16.5M | $30.3M |
| G&A | $16.4M | $23.8M | $14.0M |
| Stock-Based Comp | $2.7M | $2.4M | $2.9M |
| D&A | $3.2M | $3.7M | $4.7M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $10.2M | $-4.1M | $0 |
| Interest Expense | $301.6K | $315.3K | — |
| Interest Income | $71.1K | $585.0K | $1.3M |
| Pre-Tax Income | $-18.7M | $-42.2M | $-42.9M |
| Income Tax | $25.6K | $0 | $0 |
| Continuing Ops | $-18.7M | $-42.2M | $-42.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-18.7M | $-42.2M | $-34.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-18.7M | $-42.2M | $-34.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $22.1M | $58.9M | $23.8M |
| Cash & Equivalents | $15.0M | $56.6M | $8.9M |
| Marketable Securities | — | — | $11.9M |
| Accounts Receivable | $5.6M | $0 | — |
| Prepaid Expenses | — | $2.3M | $3.0M |
| Other Current Assets | $1.5M | $0 | $55.0K |
| Long-Term Assets | $28.8M | $25.0M | $20.4M |
| PP&E (Net) | $23.3M | $19.7M | $15.4M |
| Operating Leases | $1.2M | $1.3M | $970.3K |
| Other LT Assets | $4.4M | $4.0M | $4.1M |
| Total Assets | $50.9M | $83.9M | $44.2M |
| Current Liabilities | $15.0M | $10.8M | $8.0M |
| Accounts Payable | $3.7M | $945.9K | $1.7M |
| Current Leases | $490.8K | $669.9K | $393.4K |
| Other Current Liab | $10.8M | $9.2M | $5.9M |
| Long-Term Liabilities | $4.9M | $15.8M | $10.2M |
| LT Operating Leases | $361.2K | $635.8K | $581.1K |
| Other LT Liab | $4.5M | $15.2M | $9.7M |
| Total Liabilities | $19.8M | $26.6M | $18.2M |
| Shareholders' Equity | $31.1M | $57.3M | $26.0M |
| Paid-In Capital | $84.4M | $152.9M | $155.8M |
| Retained Earnings | $-47.9M | $-90.1M | $-124.2M |
| AOCI | — | $26.4K | $-135.4K |
| Treasury Stock | $5.5M | $5.5M | $5.5M |
| Total L&E | $50.9M | $83.9M | $44.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-18.7M | $-42.2M | $-34.1M |
| Non-Cash Adjustments | $-708.2K | $26.1M | $-433.0K |
| Working Capital Changes | $-4.0M | $-9.1M | $246.3K |
| Cash from Operations | $-23.5M | $-25.1M | $-34.3M |
| Capital Expenditures | $2.2M | $197.2K | $337.3K |
| Cash from Investing | $-2.1M | $-152.7K | $-12.0M |
| Cash from Financing | $1.1M | $66.8M | $-1.2M |
| FX Effect | $0 | $18.1K | $-241.2K |
| Net Change in Cash | $-24.5M | $41.5M | $-47.7M |
| Beginning Cash | $39.5M | $15.0M | $56.6M |
| Ending Cash | $15.0M | $56.6M | $8.9M |
Frequently Asked Questions
How does SAB Biotherapeutics, Inc. make money?
Oncology Cell Therapy Development focusing on solid tumor treatments; Collaborations and Licensing generating marketable security proceeds; Grant-funded Research supporting pre-commercial pipeline stages; Financial Services providing liquidity through securities trading.
What are the main risks for SABS?
High negative cash flow from operations indicating reliance on external financing for sustainability; Significant year-over-year revenue contraction from $23.9M in 2022 to $1.3M in 2024; Large retained earnings deficit reflecting historical losses and limited profitability track record.
What is SABS's competitive advantage?
Proprietary cell engineering technology platform enabling rapid development of personalized cancer therapies; Strong balance sheet with substantial cash reserves and paid-in capital to fund long R&D cycles; Strategic partnerships that provide marketable security proceeds without immediate commercial pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.